Medications like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound belong to a class called GLP-1 receptor agonists, originally developed to treat Type 2 diabetes and now widely prescribed for weight loss. While effective for blood sugar control and appetite suppression, these drugs have been linked to a rare but devastating condition:
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).
Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked, causing the nerve to suffer damage or die. Because the optic nerve is responsible for transmitting visual signals from the eye to the brain, this damage often results in permanent, painless vision loss—typically in one eye, though both eyes can be affected in severe cases.
There is no effective cure or treatment for NAION. In many cases, patients experience permanent vision damage that worsens over time.
Recent studies and patient reports have raised serious concerns about eye conditions linked to semaglutide and tirzepatide, the active ingredients in many popular weight loss drugs:
Despite these findings, Novo Nordisk has not updated its U.S. drug labels to include NAION warnings.
We are currently accepting cases involving vision loss or optic nerve damage related to:
Ozempic (semaglutide injection)
Wegovy (semaglutide injection for weight loss)
Rybelsus (semaglutide oral tablet)
Mounjaro (tirzepatide injection)
Zepbound (tirzepatide injection for weight loss)
These drugs are marketed as safe, but the dark side of Ozempic, Wegovy, Mounjaro, and Zepbound is becoming clearer with each new report of eye damage or sudden blindness.
The number of Ozempic, Wegovy, and Rybelsus lawsuits related to vision loss continues to rise in July 2025, with more patients filing claims for NAION (non-arteritic anterior ischemic optic neuropathy)—a condition causing sudden and often permanent blindness.
On June 24, a new study published in JAMA Ophthalmology linked semaglutide (the active ingredient in Ozempic and Wegovy) to a higher risk of neovascular age-related macular degeneration (nAMD), another serious eye condition that leads to central vision loss. Researchers found semaglutide users were twice as likely to develop nAMD compared to non-users, further highlighting growing concerns about the long-term vision risks of GLP-1 receptor agonists.
Earlier in June, a New Jersey man filed a Wegovy lawsuit, alleging the drug caused his NAION diagnosis and permanent vision loss. His complaint claims Novo Nordisk failed to warn about the potential for optic nerve damage. On June 17, twenty-one other plaintiffs also requested consolidation of their New Jersey NAION lawsuits into a state-level multicounty litigation, citing the need to streamline discovery and coordinate growing claims.
Meanwhile, legal experts and public health advocates are urging the FDA to add a black box warning to semaglutide drugs due to the risk of irreversible eye damage. This regulatory pressure follows studies from Denmark and Canada showing a statistically significant link between semaglutide and vision loss events.
Although the federal Ozempic MDL (MDL 3094) in Pennsylvania primarily covers gastroparesis claims, NAION lawsuits are now gaining momentum outside of that MDL. As of mid-2025, over 1,800 lawsuits have been filed, with more expected after the court rules on key scientific evidence under Daubert review.
Novo Nordisk has begun testing its early defense strategy by pointing to pre-existing conditions like diabetes and hypertension as alternative causes of vision loss. However, plaintiffs’ attorneys argue the company still had a legal duty to warn—even if the risk was additive—especially since many patients had no history of eye disease before taking Ozempic or Wegovy.
If you or a loved one developed sudden vision loss or optic nerve damage after using a weight loss drug like Ozempic, Wegovy, Rybelsus, or Zepbound, you may qualify for a lawsuit. Contact our team today to learn your legal options.
If you or a loved one has been injured due to the use of Ozempic, Wegovy, or Rybelsus, don’t wait to seek legal help.
Contact Salenger, Sack, Kimmel & Bavaro today for a FREE consultation.
Call (800) 675-8556 or contact us online to get started.
You may be eligible if:
To support your case, you’ll need:
Pharmacy records showing prescriptions for semaglutide or tirzepatide
Medical records confirming vision problems or NAION diagnosis
Imaging or specialist visit records
Notes from ophthalmologists or neurologists
Documentation of lost wages, out-of-pocket costs, or reduced quality of life
Patients may be entitled to significant compensation for:
Medical bills and ongoing vision care
Pain and suffering
Lost wages and reduced earning capacity
Emotional trauma and mental anguish
Loss of independence and life enjoyment
Permanent disability or blindness-related modifications
Attorneys nationwide are now filing lawsuits on behalf of individuals injured by semaglutide and tirzepatide drugs. While not yet consolidated into a multidistrict litigation (MDL), dozens of cases are under review and early settlement discussions are underway.
SSKB is actively building cases and gathering expert medical testimony to support vision loss claims against Novo Nordisk and Eli Lilly.
Time is limited. Most states have a 2-3 year statute of limitations from the date the injury occurred—or the date you discovered the link to your medication. In New York, the deadline is typically three years, but certain exceptions may apply.
We strongly encourage you to act now to protect your right to sue.
With over four decades of experience in mass tort and product liability litigation, our firm is uniquely positioned to:
Fight back against major pharmaceutical companies
Provide personalized legal support at every step
Work on a contingency-fee basis — you pay nothing unless we win
Partner with renowned medical experts to strengthen your case
If you suffered NAION, blurry vision, or blindness after using Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, we’re here to help.
📞 Call 800-675-8556 for a free case evaluation
🖊 Or complete our confidential contact form today.